Every issue, in one place
The honest weekly read on peptides, hormones, and midlife. No hype, no fear-mongering — just what the evidence actually supports.
The regulatory dust is settling — so this week, the evidence itself
The evidence gap the hype hides, what "off-label" means, and the Mayo study showing hormone therapy boosts GLP-1 weight loss by 35% — hormones-first, proven again.
The vote is being celebrated — but the real story is the gray market it's supposed to fix
Industry cheers and RFK Jr.'s fast-track wildcard, the $328M gray market the vote doesn't touch, the real documented harms, and what "Chinese peptides" actually means.
The votes are in: six of seven recommended, one rejected
The final FDA scorecard, the committee overruling its own scientists, the three legal events being collapsed into one, and why the evidence didn't change — the vote did.
The committee voted yes — and overruled its own scientists to do it
BPC-157 and KPV pass 8–6, against the FDA's own staff review. What the votes mean, what they don't, and why the evidence didn't change — the room did.
It's here: the hearing starts tomorrow, and the FDA's scientists have already said no
What "compounding" really means, the tension inside tomorrow's vote, a new GLP-1 already sold illegally, and the one peptide on the docket that's actually about midlife.
One week before the big hearing, the FDA tipped its hand — and it's a "no"
The FDA's briefing documents propose rejecting all seven peptides, what the collagen-peptide evidence really shows, and why the hyped compounds are the least proven.
The FDA's own scientists just flagged the peptides it's about to review
The agency's reviewers break ranks before the hearing, a former Surgeon General proposes the honest middle, the GLP-1 muscle question, and an HRT correction.
The FDA vote is three weeks out — and the room has quietly changed
The committee that rejected every peptide in 2024 has quietly shrunk, the HRT pendulum swings back, and why the timing window matters more than the headline.
What the FDA decides this month, and the GLP-1 bone-loss story everyone's about to misread
The July hearing that's being oversold, a second review that's relevant to midlife skin, and why the order matters more than the molecule.
Never miss an issue — get the Brief free in your inbox each week.
Subscribe to The Peptune Brief